Literature DB >> 12324764

Neoadjuvant treatment of esophageal cancer: Immunosuppression following combined radiochemotherapy.

Claus-Dieter Heidecke1, Heike Weighardt, Marcus Feith, Ulrich Fink, Frank Zimmermann, Hubert J Stein, Jörg-Rüdiger Siewert, Bernhard Holzmann.   

Abstract

BACKGROUND: The biologic effects of neoadjuvant tumor therapies on the immune system of cancer patients are largely unknown. Immune deviations may be particularly detrimental if they occur in conjunction with postoperative immunosuppression. The effects of combined radiochemotherapy (RCTx) on T cell functions in patients with squamous cell carcinoma of the esophagus were investigated.
METHODS: T cell proliferation was stimulated by incubation of peripheral blood mononuclear cells with bacterial superantigens or by exposure of enriched T cells to superantigens presented by B lymphoma cells. Cytokine production of enriched T cells was induced by cross-linking of CD3 and CD28 and the secretion of interleukin (IL)-2, IL-4, IL-10, and interferon-gamma was measured by enzyme-linked immunosorbent assay. T cell expression of human leukocyte antigen-DR (HLA-DR) molecules was determined by flow cytometry.
RESULTS: T lymphocytes from patients having undergone RCTx exhibited a significantly reduced proliferative response following stimulation with 3 independent superantigens. Cytokine production of T cells and the antigen presenting capacity of patient's peripheral blood mononuclear cells was not diminished following RCTx. T cell expression of HLA-DR was increased following RCTx.
CONCLUSIONS: RCTx of patients with squamous cell carcinoma of the esophagus results in the suppression of T lymphocyte functions. The proliferative defects of T cells after RCTx may be linked to an impaired immune surveillance of cancer and to a higher risk of surgical complications associated with esophagectomy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12324764     DOI: 10.1067/msy.2002.127166

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  20 in total

1.  Expression properties of recombinant pEgr-P16 plasmid in esophageal squamous cell carcinoma induced by ionizing irradiation.

Authors:  Cong-Mei Wu; Tian-Hua Huang; Qing-Dong Xie; De-Sheng Wu; Xiao-Hu Xu
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

2.  Construction of pETNF-P16 plasmid and its expression properties in EC9706 cell line induced by X-ray irradiation.

Authors:  Cong-Mei Wu; Tian-Hua Huang; Qing-Dong Xie; De-Sheng Wu; Xiao-Hu Xu
Journal:  World J Gastroenterol       Date:  2004-10-15       Impact factor: 5.742

3.  [Neoadjuvant therapy for squamous cell carcinoma of the esophagus].

Authors:  F Lordick
Journal:  Chirurg       Date:  2005-11       Impact factor: 0.955

4.  [Abdomino-right-thoracic esophagectomy with intrathoracic anastomosis in Barrett's cancer].

Authors:  J R Siewert; H Bartels; H J Stein
Journal:  Chirurg       Date:  2005-06       Impact factor: 0.955

5.  Combined influence of adjuvant therapy and interval after surgery on peripheral CD4(+) T lymphocytes in patients with esophageal squamous cell carcinoma.

Authors:  Yang Ling; Lieying Fan; Chunlei Dong; Jing Zhu; Yongping Liu; Yan Ni; Changtai Zhu; Changsong Zhang
Journal:  Exp Ther Med       Date:  2010-01-01       Impact factor: 2.447

Review 6.  Neoadjuvant therapy for advanced esophageal cancer: the impact on surgical management.

Authors:  Masahiko Ikebe; Masaru Morita; Manabu Yamamoto; Yasushi Toh
Journal:  Gen Thorac Cardiovasc Surg       Date:  2016-05-10

7.  Outcome, complications, and mortality of an intrathoracic anastomosis in esophageal cancer in patients without a preoperative selection with a risk score.

Authors:  Ingo Alldinger; Leila Sisic; Marcel Hochreiter; Wilko Weichert; Susanne Blank; Maria Burian; Lars Grenacher; Tom Bruckner; Jens Werner; Markus W Büchler; Katja Ott
Journal:  Langenbecks Arch Surg       Date:  2014-11-20       Impact factor: 3.445

Review 8.  [Indicators for early prediction of outcome in sepsis].

Authors:  A Novotny; K Emmanuel; H Bartels; J-R Siewert; B Holzmann
Journal:  Chirurg       Date:  2005-09       Impact factor: 0.955

9.  Preoperative therapy of esophagogastric cancer: the problem of nonresponding patients.

Authors:  S Blank; A Stange; L Sisic; W Roth; L Grenacher; F Sterzing; M Burian; D Jäger; M Büchler; K Ott
Journal:  Langenbecks Arch Surg       Date:  2012-12-07       Impact factor: 3.445

Review 10.  [Therapy of mediastinitis in patients with esophageal cancer].

Authors:  H Bartels; J R Siewert
Journal:  Chirurg       Date:  2008-01       Impact factor: 0.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.